{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:08Z","timestamp":1793065808775,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107388","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:21:15Z","timestamp":1783700475000},"page":"107388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7344-638X","authenticated-orcid":false,"given":"Mobeen","family":"Sajjad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rida","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammeullah Baig","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0001","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","article-title":"Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome","volume":"30","author":"Ammar","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.msard.2026.107388_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106229","article-title":"Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort","volume":"93","author":"Balshi","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107388_bib0003","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2026.107388_bib0004","first-page":"173","article-title":"Glucagon-like peptide-1 receptor agonist reduces neuroinflammation and ameliorates disease progression in experimental autoimmune encephalomyelitis","volume":"16","author":"Chiou","year":"2019","journal-title":"J. Neuroinflammat."},{"issue":"5","key":"10.1016\/j.msard.2026.107388_bib0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107388_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fphar.2016.00433","article-title":"Glucagon-like peptide-1 analog, liraglutide, delays onset of experimental autoimmune encephalitis in Lewis rats","volume":"7","author":"DellaValle","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global burden of disease study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107388_bib0008","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s13311-023-01390-4","article-title":"The effects of NLY01, a novel glucagon-like peptide-1 receptor agonist, on cuprizone-induced demyelination and remyelination: challenges and future perspectives","volume":"20","author":"Gharagozloo","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0009","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s13311-021-01088-5","article-title":"Therapeutic potential of a novel glucagon-like peptide-1 receptor agonist, NLY01, in experimental autoimmune encephalomyelitis","volume":"18","author":"Gharagozloo","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.msard.2026.107388_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311162","article-title":"Endothelial function in patients with multiple sclerosis: the role of GLP-1 agonists, lipoprotein subfractions, and redox balance","volume":"24","author":"Hardonova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0011","first-page":"T31","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.msard.2026.107388_bib0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.msard.2026.107388_bib0013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.09.008","article-title":"Body mass index influence interferon-beta treatment response in multiple sclerosis","volume":"288","author":"Kvistad","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107388_bib0014","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","article-title":"Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1352458514564485","article-title":"A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107388_bib0016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107388_bib0017","article-title":"Neuroprotective effect of semaglutide in an experimental model of multiple sclerosis: role of PI3K\/Akt\/GSK-3\u03b2 signaling pathway","volume":"115","author":"Sadek","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2026.107388_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/13524585261442033","article-title":"Use of semaglutide and tirzepatide among people with multiple sclerosis","author":"Salter","year":"2026","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107388_bib0019","article-title":"Glucagon-like peptide-1 receptor agonists and multiple sclerosis: pharmacovigilance analysis of the FDA adverse event reporting system","volume":"17","author":"Shirani","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107388_bib0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cns.13791","article-title":"Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway in experimental autoimmune encephalomyelitis","volume":"28","author":"Song","year":"2022","journal-title":"CNS. Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.msard.2026.107388_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103186","article-title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","volume":"19","author":"Sun","year":"2025","journal-title":"Diabetes. Metab. Syndr."},{"issue":"1","key":"10.1016\/j.msard.2026.107388_bib0022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10072-024-07701-7","article-title":"Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss","volume":"46","author":"Udawatta","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107388_bib0023","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P. (2000), The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"2","key":"10.1016\/j.msard.2026.107388_bib0024","first-page":"343","article-title":"A case of multiple sclerosis presenting with steroid-induced diabetes mellitus treated with liraglutide","volume":"83","author":"Zhang","year":"2021","journal-title":"Nagoya J. Med. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:47:41Z","timestamp":1787921261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S2211034826004232"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107388","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107388"}}